Impaired glucose regulation appears to correspond with memory decline in aging, and patients with Senile Dementia of the Alzheimer Type (SDAT) show particular abnormalities of glucose regulation as measured by neuropathological and metabolic methods. Further, several investigators have documented that normal elderly and SDAT subjects show improvement in memory function when plasma glucose is elevated to optimal levels. In a preliminary study, this improvement was accompanied by increased plasma insulin for very mild SDAT subjects. Based on these findings, the proposed study examines the effects of hyperglycemia on memory performance and glucoregulatory hormone levels in subjects with mild SDAT compared with normal elderly subjects. The study will also examine the specific effects of increased insulin levels on memory performance. Subjects will participate in three experimental and two baseline conditions: 1. hyperglycemia with plasma insulin maintained at baseline level using an islet clamp technique; 2. hyperinsulinemia with plasma glucose maintained at baseline using glucose infusion; 3. hyperglycemia with plasma insulin allowed to increase naturally; 4. baseline plasma glucose and insulin with an islet clamp; and 5. baseline plasma glucose and insulin with saline infusion. Glucoregulatory hormones and metabolites will be measured in each condition. In addition, cognitive protocols containing both memory and non-memory measures will be administered in each condition. Hormone and metabolite levels and cognitive performance will be compared across conditions to determine if cognitive facilitation occurs in experimental relative to baseline conditions, and if such facilitation is accompanied by corresponding hormonal changes. The results of the proposed study should provide important information about the specific mechanisms disrupting glucose regulation in SDAT, as well as about the role of these mechanisms in producing the cognitive deficits that characterize the disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG010880-02
Application #
2052106
Study Section
Human Development and Aging Subcommittee 3 (HUD)
Project Start
1992-09-10
Project End
1994-09-30
Budget Start
1993-08-01
Budget End
1994-09-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Washington University
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cholerton, Brenna; Baker, Laura D; Craft, Suzanne (2013) Insulin, cognition, and dementia. Eur J Pharmacol 719:170-9
Baker, Laura D; Bayer-Carter, Jennifer L; Skinner, Jeannine et al. (2012) High-intensity physical activity modulates diet effects on cerebrospinal amyloid-? levels in normal aging and mild cognitive impairment. J Alzheimers Dis 28:137-46
Cudaback, Eiron; Li, Xianwu; Yang, Yue et al. (2012) Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation. J Neuroinflammation 9:192
Sonnen, J A; Larson, E B; Walker, R L et al. (2010) Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 75:1203-10
Craft, Suzanne (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147-52
Watson, G Stennis; Craft, Suzanne (2006) Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 245:21-33
Kulstad, J J; Green, P S; Cook, D G et al. (2006) Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 66:1506-10
Pedersen, Ward A; McMillan, Pamela J; Kulstad, J Jacob et al. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199:265-73
Watson, G Stennis; Bernhardt, Tanja; Reger, Mark A et al. (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 27:38-41
Craft, Suzanne (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20:298-301

Showing the most recent 10 out of 23 publications